<ENAMEX TYPE="ORGANIZATION">Cytogen Corp.</ENAMEX> said it applied to the <ENAMEX TYPE="ORGANIZATION">Food and Drug Administration</ENAMEX> for approval to market an imaging agent to diagnose colo-rectal cancer. The agent is a monoclonal-antibody trade named <ENAMEX TYPE="PERSON">Oncoscint CR103</ENAMEX>.
